Drugs / MSA-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07446894 | Feb 2026 → Mar 2028 expected | multiple system atrophy | Tokyo University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSA-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07446894 ↗ |
| Known as | ubiquinol | “MSA-01 (ubiquinol), a highly bioavailable form of CoQ10” NCT07446894 ↗ |
| Route | Oral | “receive oral MSA-01 or placebo for 52 weeks” NCT07446894 ↗ |